Compare PBFS & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PBFS | ALLO |
|---|---|---|
| Founded | 1889 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 440.6M | 452.6M |
| IPO Year | 2019 | 2018 |
| Metric | PBFS | ALLO |
|---|---|---|
| Price | $17.41 | $0.63 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 10.2K | ★ 11.4M |
| Earning Date | 10-30-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 36.07 | 34.09 |
| EPS | ★ 0.36 | N/A |
| Revenue | ★ $15,814,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $180.53 |
| P/E Ratio | $48.83 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $13.05 | $0.65 |
| 52 Week High | $19.91 | $4.46 |
| Indicator | PBFS | ALLO |
|---|---|---|
| Relative Strength Index (RSI) | 36.35 | 17.76 |
| Support Level | $16.80 | N/A |
| Resistance Level | $18.09 | $2.22 |
| Average True Range (ATR) | 0.50 | 0.09 |
| MACD | -0.12 | -0.03 |
| Stochastic Oscillator | 0.00 | 0.05 |
Pioneer Bancorp Inc is involved in providing banking services. These services include Personal services such as Checking, Savings, eBanking Cards, and Business services such as Business Deposit and operating Accounts, Business eBanking, and Business loans. Some of the other services of the company include Government Banking, Wealth Management, Benefits Consulting and Insurance.
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).